On April 29th, A-share listed company Haixiang Pharmaceutical (002099) (002099) released its annual report for 2023. Of which, the net loss is 4.Pokerdiningtable20 billion yuan to stop profits and turn losses.
According to the financial diagnosis model of flush (300033), there are more than 1200 financial indicators of its financial data in the current period and in the past 5 years.PokerdiningtableAccording to the comprehensive operation and follow-up analysis, the overall financial situation of Haixiang Pharmaceutical Company in the past five years is lower than the average level of the industry. Specifically, the quality of cash flow and assets is average.
A net loss of 420 million yuan, from profit to loss
In terms of revenue and profit, the company achieved a total operating income of 2.172 billion yuan in the reporting period, down 19.68% from the same period last year, with a net loss of 420 million yuan, and a net profit of 88.0137 million yuan in the same period last year, and basic earnings per share of-0.26 yuan.
In terms of assets, during the company's reporting period, the total assets at the end of the period were 7.52 billion yuan and accounts receivable were 425 million yuan; in terms of cash flow, the net cash flow generated by business activities was 241 million yuan, and the cash received by selling goods and providing services was 1.704 billion yuan.
Growth indicator is the only bright spot in the financial report.
According to the relevant financial information released by Haixiang Pharmaceutical, the growth index is the only bright spot. The non-net profit deducted for the current period increased by 3573.35% compared with the same period last year, and the profit growth was excellent.
The financial situation is poor and there are 8 financial risks.
According to the relevant financial information released by Haixiang Pharmaceutical Co., Ltd., the company has eight financial risks, as follows:
The average rate of return on net assets is-1.19%, and the company's profitability is poor. The average operating profit margin is-3.93%, and the company's ability to make money is poor. The average year-on-year growth rate of performance deduction non-net profit is-1563.06%, and the growth of the company is very low. The average year-on-year growth rate of revenue is-8.95%, and the growth of the company is poor. The average year-on-year growth rate of growth operating profit is-331.39%, and the company's growth ability is very weak. The liquidity ratio is 1.49, and the short-term solvency is very weak. The average cash-to-cash ratio of the main business is 73.94%, and the company's cash flow is weak. Revenue in the growth period decreased by 16.65% compared with the same period last year, with a higher decline in revenue.Overall, the overall financial situation of Haixiang Pharmaceutical Industry is lower than the industry average, with a current total score of 0.95, ranking low among 156 companies in its chemical pharmaceutical industry. Specifically, the quality of cash flow and assets is average.
The scores of the indicators are as follows:
Index type previous period score ranking evaluation cash flow 2.391.41113 general asset quality 1.971.38114 general solvency 0.640.80132 lower profitability 0.510.13153 lower growth ability 0.990.10154 weaker operating ability 2.932.6674 the total score is 1.290.95147 lower than the industry averageOn the large model of financial diagnosis of flush
Flush (300033) Financial diagnosis model calculates the company's financial scores, highlights and risks based on the company's latest and previous financial data and industry conditions, reflecting the company's disclosed financial position, but not a forecast of the future financial position. The financial score range is 0-5. The higher the score, the better the financial situation and the greater the value of the medium-and long-term investment. In the financial highlights and risk reviews, the five-year average of the indicators related to the "average" keyword, and the latest reporting period data without the "average" keyword. All the above information is based on artificial intelligence algorithm, for reference only, does not represent flush financial point of view, investors operate accordingly, at their own risk.
Learn more about the company's stock diagnostic information >
(: congratulations